Ascendis Pharma Company Insiders
ASND Stock | USD 136.38 1.36 0.99% |
Ascendis Pharma employs about 879 people. The company is managed by 15 executives with a total tenure of roughly 42 years, averaging almost 2.0 years of service per executive, having 58.6 employees per reported executive. Evaluation of Ascendis Pharma's management performance can provide insight into the firm performance.
Jan Mikkelsen CEO CEO and President Member of Executive Board and Executive Director |
Flemming Jensen President Senior Vice President Product Supply |
Ascendis |
Ascendis Pharma's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Ascendis Pharma's future performance. Based on our forecasts, it is anticipated that Ascendis will maintain a workforce of about 880 employees by January 2025.Ascendis Pharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.2792) % which means that it has lost $0.2792 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.1843) %, meaning that it created substantial loss on money invested by shareholders. Ascendis Pharma's management efficiency ratios could be used to measure how well Ascendis Pharma manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 3.47, whereas Return On Tangible Assets are forecasted to decline to (0.62). At present, Ascendis Pharma's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 374.1 M, whereas Non Current Assets Total are forecasted to decline to about 79.4 M.As of December 23, 2024, Common Stock Shares Outstanding is expected to decline to about 39.2 M. The current year's Net Loss is expected to grow to about (498.6 M)
Ascendis Pharma Workforce Comparison
Ascendis Pharma AS is rated third in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 17,067. Ascendis Pharma holds roughly 879 in number of employees claiming about 5% of equities under Health Care industry.
Ascendis Pharma Profit Margins
The company has Profit Margin (PM) of (1.54) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (3.7) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $3.7.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.57 | 0.8336 |
|
|
Ascendis Pharma AS Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Ascendis Pharma AS Price Series Summation is a cross summation of Ascendis Pharma price series and its benchmark/peer.
Ascendis Pharma Notable Stakeholders
An Ascendis Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Ascendis Pharma often face trade-offs trying to please all of them. Ascendis Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Ascendis Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Jan Mikkelsen | CEO and President Member of Executive Board and Executive Director | Profile | |
Flemming Jensen | Senior Vice President Product Supply | Profile | |
Scott Smith | CFO, Senior Vice President | Profile | |
Peter Rasmussen | Principal Accounting Officer and VP of Fin. | Profile | |
Michael LLM | Chief VP | Profile | |
Birgitte MD | Sr Affairs | Profile | |
Stina MD | Executive Oncology | Profile | |
Scott Holmes | Head Endocrinology | Profile | |
Timothy Lee | Director Relations | Profile | |
Nyssa Noyola | Vice Management | Profile | |
Jens Okkels | VP Devel | Profile | |
Mads Bodenhoff | Senior Officer | Profile | |
Joseph Kelly | Head Endocrinology | Profile | |
Lotte Sonderbjerg | Sr Officer | Profile | |
Kennett Sprogoe | Executive Development | Profile |
About Ascendis Pharma Management Performance
The success or failure of an entity such as Ascendis Pharma AS often depends on how effective the management is. Ascendis Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Ascendis management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Ascendis management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.59) | (0.62) | |
Return On Capital Employed | (0.73) | (0.69) | |
Return On Assets | (0.58) | (0.61) | |
Return On Equity | 3.30 | 3.47 |
Please note, the presentation of Ascendis Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ascendis Pharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Ascendis Pharma's management manipulating its earnings.
Ascendis Pharma Workforce Analysis
Traditionally, organizations such as Ascendis Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Ascendis Pharma within its industry.Ascendis Pharma Manpower Efficiency
Return on Ascendis Pharma Manpower
Revenue Per Employee | 303.4K | |
Revenue Per Executive | 17.8M | |
Net Loss Per Employee | 547.7K | |
Net Loss Per Executive | 32.1M | |
Working Capital Per Employee | 574.9K | |
Working Capital Per Executive | 33.7M |
Complementary Tools for Ascendis Stock analysis
When running Ascendis Pharma's price analysis, check to measure Ascendis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascendis Pharma is operating at the current time. Most of Ascendis Pharma's value examination focuses on studying past and present price action to predict the probability of Ascendis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascendis Pharma's price. Additionally, you may evaluate how the addition of Ascendis Pharma to your portfolios can decrease your overall portfolio volatility.
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |